SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and ...
BEIJING and BURLINGTON, Mass. , Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of ...
CRISPR screening libraries for chicken and pig allow the study of gene disruptions in a single experiment to enable improved breeding and more MOUNTAIN VIEW, Calif. , Oct. 9, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the ...
NEW YORK , Sept. 27, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the outcome of the U.S. Food and Drug ...
Base Pair Biotechnologies, "The Aptamer Discovery Company™" has been recently awarded a grant from NIH entitled, "Aptamer engineering of lentiviral vectors for cardiac gene therapies". HOUSTON , Sept. 27, 2023 /PRNewswire-PRWeb/ -- ...
SUZHOU, China and HONG KONG , Sept. 14, 2023 /PRNewswire/ -- Cure Genetics and Frametact Limited , a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a ...
WATERTOWN, Mass. , Sept. 12, 2023 /PRNewswire/ -- Fluent BioSciences, a cutting edge life sciences company leading the charge in revolutionizing single cell analysis through simple, cost-effective, and highly scalable single-cell RNA ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal of ...
Phase 2 efficacy study to be initiated in H1 2024 New data published in Nucleic Acid Therapeutics demonstrate broad distribution, as well as cell and nucleus penetration of SPL84 in lungs of animal models, overcoming ...
Cross-cohort analysis found novel variant in GBA1 gene associated with higher risk of Parkinson's in people of African ancestry Finding is from Nigerian and U.S. cohorts contributing to the Global Parkinson's Genetics Program (GP2), a ...
Genetic predisposition towards greater muscle strength is associated with a longer lifespan and reduced vulnerability to common diseases, based on analysis of health and genome...
Stem cell therapy emerges as a viable and safe choice for individuals grappling with challenging traumatic spinal cord injuries , said experts ( ). Stem Cell Therapy’s Safety and Promising Benefits "This study documents the safety and ...
Researchers from the National Institutes of Health (NIH), US have identified over 275 million genetic variants that were not previously reported. This undiscovered pool of variants opens up new avenues for comprehending the genetic factors impacting ...
CDD - CDKL5 deficiency disorder, a most common type of genetic epilepsy in children, occurs due to the loss of genes producing the CDKL5 enzyme. Scientists at the Francis Crick...
Leveraging genetic mapping, scientists pinpointed a gene on human chromosome 21 named Dyrk1a. In the mouse model of Down syndrome , having three copies of this gene leads to heart defects . While Dyrk1a has been associated with cognitive impairment and facial changes in Down syndrome, its involvement in heart development was previously unknown. ( ) Down syndrome affects around 1 in 800 new births and is caused by an extra third copy of chromosome 21. About half of babies born with Down syndrome have heart defects, such as a failure of the heart to separate into four chambers, leaving a ‘hole in the heart’. If the heart defects are very serious, high-risk surgery might be needed soon after birth and people often require ongoing monitoring of the heart for the rest of their life. Therefore, better treatment options are needed and this must be guided by knowledge of which of the extra 230 genes on chromosome 21 are responsible for the heart defects. But before this study the identity of these causative genes was not known. In research published today in Science Translational Medicine , the team at the Crick and UCL studied human Down syndrome fetal hearts as well as embryonic hearts from a mouse model of Down syndrome. An extra copy of Dyrk1a turned down the activity of genes required for cell division in the developing heart and the function of the mitochondria, which produce energy for the cells. These changes correlated with a failure to correctly separate the chambers of the heart. Unveiling the Missing Link in Down Syndrome Heart Defects The team found that while Dyrk1a is required in three copies to cause heart defects in mice, it was not sufficient alone. Thus, another unknown gene must also be involved in the origin of heart defects in Down syndrome. The team is currently searching for this second gene. Dyrk1a codes for an enzyme called DYRK1A. The researchers tested a DYRK1A inhibitor on mice pregnant with pups that model the hearts defects in Down syndrome, as their hearts were forming. When DYRK1A was inhibited, the genetic changes were partially reversed and the heart defects in the pups were less severe. Victor Tybulewicz, Group Leader of the Immune Cell Biology Laboratory & Down Syndrome Laboratory, said: “Our research shows that inhibiting DYRK1A can partially reverse changes in mouse hearts, suggesting that this may be a useful therapeutic approach. “However, in humans the heart forms in the first 8 weeks of pregnancy, likely before a baby could be screened for Down syndrome, so this would be too early for treatment. The hope is that a DYRK1A inhibitor could have an effect on the heart later in pregnancy, or even better after birth. These are possibilities we are currently investigating.” This research forms part of the lab’s overall goal to understand the genetics behind all aspects of Down syndrome. Eva Lana-Elola, Principal Laboratory Research Scientist at the Crick, and co-first author, said: “It was remarkable that just restoring the copy number of one gene from 3 to 2 reversed the heart defects in the mouse model for Down syndrome. We’re now aiming to understand which of the other genes on this extra chromosome are involved. Even though Dyrk1a isn’t the only gene involved, it’s clearly a major player in many different aspects of Down syndrome.” Rifdat Aoidi, Postdoctoral Project Research Scientist at the Crick, and co-first author, said: “We don’t yet know why the changes in cell division and mitochondria mean the heart can’t correctly form chambers. Dysfunction in the mitochondria has also been linked to cognitive impairment in Down syndrome, so boosting mitochondrial function could be another promising avenue for therapy.” Reference: Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome - (https:...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers